Aggressive Supportive Care Following Novel Agents May Reduce Infection

Linvoseltamab, a BCMA bispecific antibody, showed efficacy in relapsed/refractory multiple myeloma with an objective response rate of 70.9%, but requires aggressive supportive care to manage high infection risks, especially in communities without clinical trial experience. The importance of supportive care, including intravenous immunoglobulin, and potentially reducing dosing frequency to mitigate infection risks, was emphasized.